539 related articles for article (PubMed ID: 17340591)
21. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
Cheung R; Tucker SL; Lee AK; de Crevoisier R; Dong L; Kamat A; Pisters L; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):993-1002. PubMed ID: 15752878
[TBL] [Abstract][Full Text] [Related]
22. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
[TBL] [Abstract][Full Text] [Related]
23. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.
Hurwitz MD; Halabi S; Ou SS; McGinnis LS; Keuttel MR; Dibiase SJ; Small EJ
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):814-9. PubMed ID: 18407435
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH
Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848
[TBL] [Abstract][Full Text] [Related]
25. Anatomy-based inverse planning dose optimization in HDR prostate implant: a toxicity study.
Mahmoudieh A; Tremblay C; Beaulieu L; Lachance B; Harel F; Lessard E; Pouliot J; Vigneault E
Radiother Oncol; 2005 Jun; 75(3):318-24. PubMed ID: 16086913
[TBL] [Abstract][Full Text] [Related]
26. [Acute adverse effects of high dose brachytherapy in combination with external radiotherapy in localized prostate cancer].
Soumarová R; Homola L; Stursa M; Perková H
Cas Lek Cesk; 2006; 145(1):43-9. PubMed ID: 16468241
[TBL] [Abstract][Full Text] [Related]
27. High dose rate and external beam radiotherapy in locally advanced prostate cancer.
Viani GA; Pellizzon AC; Guimarães FS; Jacinto AA; dos Santos Novaes PE; Salvajoli JV
Am J Clin Oncol; 2009 Apr; 32(2):187-90. PubMed ID: 19307949
[TBL] [Abstract][Full Text] [Related]
28. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
[TBL] [Abstract][Full Text] [Related]
29. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer.
Deger S; Boehmer D; Roigas J; Schink T; Wernecke KD; Wiegel T; Hinkelbein W; Budach V; Loening SA
Eur Urol; 2005 Apr; 47(4):441-8. PubMed ID: 15774239
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.
Stock RG; Klein TJ; Cesaretti JA; Stone NN
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):753-8. PubMed ID: 19084351
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features.
Dattoli M; Wallner K; True L; Cash J; Sorace R
Cancer; 2007 Aug; 110(3):551-5. PubMed ID: 17577217
[TBL] [Abstract][Full Text] [Related]
32. Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy.
Cheung R; Tucker SL; Lee AL; Dong L; Kamat A; Pisters L; Kuban DA
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):14-9. PubMed ID: 15629589
[TBL] [Abstract][Full Text] [Related]
33. Accelerated partial breast irradiation: an analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose-rate interstitial brachytherapy.
Wazer DE; Kaufman S; Cuttino L; DiPetrillo T; Arthur DW
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):489-95. PubMed ID: 16246495
[TBL] [Abstract][Full Text] [Related]
34. Acute toxicity of conformal high dose interstitial brachytherapy boost in prostate cancer.
Soumarová R; Homola L; Stursa M; Perková H
Neoplasma; 2006; 53(5):410-7. PubMed ID: 17013535
[TBL] [Abstract][Full Text] [Related]
35. Late rectal toxicity after prostate brachytherapy: influence of supplemental external beam radiation on dose-volume histogram analysis.
Kalakota K; Rakhno E; Pelizzari CA; Jani AB; Liauw SL
Brachytherapy; 2010; 9(2):131-6. PubMed ID: 19853533
[TBL] [Abstract][Full Text] [Related]
36. Four-year experience of interstitial permanent brachytherapy for Japanese men with localized prostate cancer.
Ishiyama H; Satoh T; Kitano M; Tsumura H; Kotani S; Okusa H; Uemae M; Baba S; Hayakawa K
Jpn J Clin Oncol; 2008 Jul; 38(7):469-73. PubMed ID: 18577509
[TBL] [Abstract][Full Text] [Related]
37. Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer.
Izard MA; Haddad RL; Fogarty GB; Rinks A; Dobbins T; Katelaris P
Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):38-47. PubMed ID: 16904516
[TBL] [Abstract][Full Text] [Related]
38. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer.
Phan TP; Syed AM; Puthawala A; Sharma A; Khan F
J Urol; 2007 Jan; 177(1):123-7; discussion 127. PubMed ID: 17162020
[TBL] [Abstract][Full Text] [Related]
39. Cancer control after low-dose-rate prostate brachytherapy performed by a multidisciplinary team with no previous prostate brachytherapy experience.
McMullen KP; deGuzman AF; McCullough DL; Lee WR
Urology; 2004 Jun; 63(6):1128-31. PubMed ID: 15183965
[TBL] [Abstract][Full Text] [Related]
40. Colorectal complications of external beam radiation versus brachytherapy for prostate cancer.
Lesperance RN; Kjorstadt RJ; Halligan JB; Steele SR
Am J Surg; 2008 May; 195(5):616-20; discussion 620. PubMed ID: 18374892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
